Clinical Trials
25 trialsNCT03331250 2025-12-23
Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT02625389 2025-10-10
A Study to Evaluate How Safe and Effective is the Mixture of Lipiodol® Ultra Fluid and Glue When Used for Embolization Procedures
Guerbet
Phase 4 Completed
NCT02815995 2025-06-12
Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04996004 2024-12-11
TTI-621-03
Pfizer
Phase 2 Terminated
NCT02584309 2023-11-07
Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
Washington University School of Medicine
Phase 2 Completed
NCT01344018 2023-04-24
STRASS
European Organisation for Research and Treatment of Cancer - EORTC
Phase NA Completed
NCT03921073 2022-11-01
Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT01462630 2022-08-19
Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma
Fox Chase Cancer Center
Phase 2 Completed
NCT00346164 2022-04-28
Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
Children's Oncology Group
Phase 3 Completed
NCT02048722 2022-04-25
Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma
Northwestern University
Phase 2 Completed
NCT02212015 2022-03-22
EVA
Heidelberg University
Phase 2 Terminated
NCT01532687 2021-09-27
Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma
OHSU Knight Cancer Institute
Phase 2 Completed
NCT01975519 2020-05-20
A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma
Tracon Pharmaceuticals Inc.
Phase 1/2 Completed
NCT02979899 2020-05-12
TAPPAS
Tracon Pharmaceuticals Inc.
Phase 3 Completed
NCT01614795 2018-12-11
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT01154452 2018-08-15
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00288015 2018-06-25
Bevacizumab in Treating Patients With Angiosarcoma
Northwestern University
Phase 2 Completed
NCT01055028 2018-03-26
Paclitaxel + Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma
Stanford University
Phase 2 Terminated
NCT00112463 2017-06-14
Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00887809 2016-01-25
Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00474994 2016-01-20
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01623869 2015-10-19
Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT01132547 2015-07-02
Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer
University of South Florida
Phase 3 Terminated
NCT00245102 2014-05-23
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00217620 2014-05-15
S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas
National Cancer Institute (NCI)
Phase 2 Completed